✨ Free AI Report
Santen Pharmaceutical Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Santen Pharmaceutical Co., Ltd.
Company Research

Santen Pharmaceutical Co., Ltd.: Business Overview, Financials & Competitive Analysis

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products, operating globally with trailing twelve month revenue of ¥287,994 million. The company specializes in glaucoma treatmen...

Analyst-debate audio for Santen Pharmaceutical Co., Ltd.

AskCyborg analysts argue the bull and bear cases for Santen Pharmaceutical Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Margin-expanding ophthalmic pharma with strong earnings momentum trading near fair value despite modest topline growth...

Read the full analyst-debate transcript →
Industry Pharmaceutical Manufacturing - Ophthalmology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Santen Pharmaceutical Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Santen Pharmaceutical Co., Ltd. Overview

Pro stress-test →

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products, operating globally with trailing twelve month revenue of ¥287,994 million. The company specializes in glaucoma treatments and has an extensive clinical pipeline targeting multiple eye disease indications.

Strategic Profile

Pro stress-test →

Santen demonstrates improving margins with trailing net profit margin of 10.8% compared to 8.6% a year earlier, alongside 20.2% earnings growth over the last 12 months. The company faces modest 2.5% revenue growth forecast versus the broader JP market and relies on margin support for value creation, positioning it as a profitability-driven play rather than a growth story.

Competitive Landscape

Pro stress-test →

Santen competes primarily in the global ophthalmic pharmaceutical market against major players like Allergan (AbbVie), Bausch + Lomb, and Sun Pharmaceutical. The company differentiates through its focused ophthalmic portfolio, particularly in glaucoma treatments where it holds established market positions, and its advancing pipeline for adjacent indications like myopia and dry eye. The therapeutic focus creates a defensible niche versus diversified pharma competitors.

Industry Context

Santen Pharmaceutical Co., Ltd. operates in Pharmaceutical Manufacturing - Ophthalmology.

Key facts

Founded: 1890 · Headquarters: Osaka, Japan · Revenue: ¥288.0B · Market cap: ¥553.6B (~$3.5B)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Santen Pharmaceutical Co., Ltd..

  • Net profit margins expanded from 8.6% to 10.8% year-over-year, supporting 20.2% earnings growth
  • DCF fair value of ¥3,500 versus current price of ¥1,719 suggests 103% upside, while modest P/E premium indicates market skepticism
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Nine-month sales and net income declined year-over-year, with EPS softening despite 90-day share price momentum
  • Feb 2026Trading at P/E 18.2x above peer average, but DCF valuation suggests 50% upside potential
  • +1 moreTrack every material event for Santen Pharmaceutical Co., Ltd. as it happens. Explore monitoring →
Get alerted when Santen Pharmaceutical Co., Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Allergan AestheticsLeading global ophthalmic pharma with dominant glaucoma and aesthetic franchises→Bausch VisionMajor ophthalmic pharma and medical devices focused on eye care solutions→Sun Pharma OphthalmologyGeneric and branded ophthalmic pharmaceuticals with global reach→

Compare Santen Pharmaceutical Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Santen Pharmaceutical Co., Ltd. operates in Pharmaceutical Manufacturing - Ophthalmology. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Manufacturing - Ophthalmology research →
NEW · MCP server

Ask your AI assistant about Santen Pharmaceutical Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Santen Pharmaceutical Co., Ltd. and its top competitor on Cyborg Score”
“What did Santen Pharmaceutical Co., Ltd. do this quarter?”
“Is Santen Pharmaceutical Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Santen Pharmaceutical Co., Ltd. do?+
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products, operating globally with trailing twelve month revenue of ¥287,994 million. The company specializes in glaucoma treatmen...
What is Santen Pharmaceutical Co., Ltd.'s Cyborg Score?+
Santen Pharmaceutical Co., Ltd. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Santen Pharmaceutical Co., Ltd.'s main competitors?+
Named competitors include Allergan Aesthetics, Bausch Vision, Sun Pharma Ophthalmology. The full competitive landscape is in the AskCyborg report.
How can I get the full Santen Pharmaceutical Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Santen Pharmaceutical Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Santen Pharmaceutical Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.